Suppr超能文献

慢性炎症性脱髓鞘性多发性神经病中的最小有意义差异和自我识别的治疗反应。

Minimal important differences and self-identifying treatment response in chronic inflammatory demyelinating polyneuropathy.

机构信息

Inflammatory Neuropathy Clinic, Department of Neurology, University Hospitals Birmingham, Birmingham, UK.

Aston Medical School, Aston University, Birmingham, UK.

出版信息

Muscle Nerve. 2021 Jul;64(1):37-42. doi: 10.1002/mus.27250. Epub 2021 Apr 20.

Abstract

INTRODUCTION/AIM: The use of outcome measures is recommended for chronic inflammatory demyelinating polyneuropathy (CIDP). Implications of minimal important differences (MID) to ascertain responder status are unknown. The reliability of patient-reported treatment-response in relation to clinically relevant change is also unknown.

METHODS

We retrospectively studied 72 subjects with "definite" or "probable" CIDP evaluated at pre-specified time-intervals pre- and post-treatment. We derived MID and the minimum detectable change with 95% confidence intervals (MDC ) for four scales. Scale sensitivities were determined with applicable MID-defined cutoffs (aMIDc), to detect subjects with self-identifying treatment response through a single question.

RESULTS

The use of MID was not valid for the Medical Research Council Sum Score, as MDC  > MID. The aMIDc for the Overall Neuropathy Limitation Score (ONLS) was 1 (sensitivity: 84.7%). The aMIDc for the centile Inflammatory Rasch-built Overall Disability Scale (cI-RODS) was 8 (sensitivity: 62.3%). The aMIDc for grip strength was 4 kg (sensitivity: 79.1%). MID-defined amelioration of any one scale among ONLS, cI-RODS, or grip strength, significantly improved sensitivity to detect treatment-responders compared with the ONLS alone (McNemar test: P = .008, odds ratio: 3.36 [95% confidence interval: 1.44-7.86]). Patient-reported improvement was highly reliable in relation to MID-defined amelioration on any one scale.

DISCUSSION

In subjects with CIDP, MID-defined amelioration of any one of three commonly used outcome measures offers optimum relevance and sensitivity to detect self-identifying treatment-responders. Patient reliability to single-question ascertainment of response is high in relation to MID-defined clinical relevance. These findings support use of multiple outcome measures in CIDP monitoring and justify enhanced patient involvement in the process.

摘要

简介/目的:推荐使用结局测量来评估慢性炎症性脱髓鞘性多发性神经病(CIDP)。最小有意义差异(MID)来确定应答者状态的影响尚不清楚。与临床相关变化相关的患者报告治疗反应的可靠性也未知。

方法

我们回顾性研究了 72 名在治疗前后预先指定时间间隔接受“明确”或“可能”CIDP 评估的受试者。我们为四个量表推导了 MID 和 95%置信区间(MDC)的最小可检测变化。应用适用的 MID 定义的截断值(aMIDc)确定量表敏感性,以通过单个问题检测自我识别的治疗反应。

结果

MID 不适用于医学研究委员会总和评分,因为 MDC > MID。总体神经病变限制评分(ONLS)的 aMIDc 为 1(敏感性:84.7%)。百分炎症 Rasch 构建总体残疾量表(cI-RODS)的 aMIDc 为 8(敏感性:62.3%)。握力的 aMIDc 为 4 公斤(敏感性:79.1%)。与单独的 ONLS 相比,ONLS、cI-RODS 或握力中任何一个量表的 MID 定义的改善都显著提高了检测治疗应答者的敏感性(McNemar 检验:P=0.008,优势比:3.36[95%置信区间:1.44-7.86])。与任何一个量表的 MID 定义的改善相关的患者报告的改善具有高度可靠性。

讨论

在 CIDP 患者中,三个常用结局测量中的任何一个的 MID 定义的改善提供了最佳的相关性和敏感性,以检测自我识别的治疗应答者。与 MID 定义的临床相关性相关,患者对单一问题确定反应的可靠性很高。这些发现支持在 CIDP 监测中使用多种结局测量,并证明了增强患者参与该过程的合理性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验